Kornimate/medical-research-clean huggingface dataset:
efficacy and safety of loxoprofen hydrogel patch in patients with ankylosing spondylitis

Conditions: Ankylosing Spondylitis

Summary: to assess the efficacy and safety of loxoprofen sodium hydrogel patch (lx-p) versus loxoprofen sodium tablet (lx-t) in patients with active ankylosing spondylitis(as). the trial includes 70 patients who are randomly assigned to either the lx-p group (lx-p 100 mg per day) or lx-t group (lx-t 60 mg t.i.d.) for 4 weeks.

this is a 4-week randomized, open-label trial to investigate the efficacy and safety of loxoprofen sodium hydrogel patch (lx-p) versus loxoprofen sodium tablet (lx-t) in patients with active ankylosing spondylitis(as). the trial includes 70 patients who are randomly assigned to either the lx-p group (lx-p 100 mg per day) or lx-t group (lx-t 60 mg t.i.d.) for 4 weeks.

Eligibility criteria:
inclusion criteria: * 18 to 65 years * meet 1984 modified new york criteria for as * the bath as disease activity index (basdai) ≥4 on a 0-10-cm visual analog scale or the ankylosing spondylitis disease activity score using the c-reactive protein level (asdas-crp) ≥1.3 * nsaids washout period of at least 5 days prior to randomization * dmards washout period of at least 4 weeks prior to randomization * corticosteroids washout period of at least 4 weeks prior to randomization * biological agents washout period of at least 3 months prior to randomization. exclusion criteria: * peptic ulcer * unstable cardiac diseases * abnormal hepatic function with an elevation of alanine aminotransferase (alt) or aspartate aminotransferase (ast) ≥ 2.5 times of upper normal limits * abnormal renal function with creatinine more than upper normal limit * hematologic disorders * psychosis * malignancy * allergic to lx drug.

Keywords: ankylosing spondylitis loxoprofen patch
the efficacy of cervical lordosis rehabilitation for nerve root function and pain in cervical spondylotic radiculopathy

Conditions: Cervical Lordosis Rehabilitation

Summary: to test the hypothesis that improvement of cervical lordosis (cl) in cervical spondylotic radiculopathy (csr) will improve clinical features in a population suffering from csr. thirty chronic lower csr patients with cl \< 25° will be included. patients will be assigned randomly into two equal groups, study and control . both groups will receive neck stretching and exercises and infrared; additionally the study group will receive cervical extension traction. treatments will be applied 3 time per week for 10 weeks after which groups will be followed for 3-months and 2-years. amplitude of dermatomal somatosensory evoked potentials (dsseps), cervical lordosis, and pain scales (nrs) will be measured.

previous studies testing the effects of 3-point bending types of cervical traction, have not clarified exactly what impact the sagittal cervical curve correction has on nerve root function and pain responses associated with improving an abnormal cervical lordosis in cervical spondylotic patients. the present randomized controlled trial will be undertaken to investigate the neurophysiological and pain response outcomes of 3-point bending (2-way) traction compared to standard care in patient cases with lower cervical spine csr, chronic pain, and with a verified hypo-lordosis of the cervical spine. the primary hypothesis of this study will be that cervical lordosis restoration will have short- and long-term effects on dsseps and pain outcomes in csr patients.

Eligibility criteria:
inclusion criteria: * unilateral radiculopathy due to spondylotic changes of the lower cervical spine * absolute rotatory angle is less than 20° * side to side amplitude differences of 50% or more in dermatomal somatosensory evoked potentials measurement exclusion criteria: * central spinal canal stenosis * rheumatoid arthritis * vestibulobasilar insufficiency * osteoporosis * inability to tolerate the cervical extension position

Keywords: cervical spine lordosis dermatomal traction
patient experience data in radiation oncology

Conditions: Radiotherapy Side Effect; PROMs

Summary: the project is part of the overarching goal of improving patient-centric radiation oncology. this pilot project aims to develop an instrument that can be used to collect clinically relevant patient-reported outcome data on adverse effects during and after rt. this real-world evidence (rwe) database will be the basis to monitor and evaluate future technological developments, combination treatments (e.g. radioimmunotherapy, etc.), or changes in treatment protocols. the pseudonymized data will be linked to data in the oncological information system and dosimetric data from the treatment planning system. in this way, they represent a basic building block of patient-oriented development of clinical radiotherapy.


Eligibility criteria:
inclusion criteria: * all patients receiving external beam radiotherapy exclusion criteria: * unable to independently answer questionnaires on radiation-induced side effects

Keywords: radiation oncology patient reported outcome
prevalence, risk factors and outcomes of pediatric vascular thrombosis

Conditions: Vascular Thrombosis

Summary: this study is aimed to identify the prevalence, risk factors and outcomes of children with either venous or arterial thromboembolism admitted to children hospital assiut university aiming at early detection and avoidance of catastrophic complications .

thrombosis is a blood clot that develops within veins or sometimes arteries in the body. occur most commonly in the inferior and superior vena cava, their major tributaries, the deep veins of the extremities, the splanchnic veins, as well as the cerebral venous sinuses. the incidence of venous thromboembolism (vte) increases with age. in the pediatric population (0-18 years) the incidence is approximately 0.7-2.1 cases per 100,000 children,1-3 while in the adult population the incidence is 100-150 per 100,000.4 risk factors include the presence of central venous lines, trauma, major surgery followed by bedrest, immobilization, infection (cellulitis, osteomyelitis, phlebitis), cancer chemotherapy, inflammatory bowel disease, nephrotic syndrome, obesity, dehydration, and total parenteral nutrition. patients with vascular thromboembolism present with various symptoms depending on site of thrombosis , symptoms include swelling, redness, pain , low-grade fever in cases that develop pulmonary embolism they experience chest pain and shortness of breath that begin suddenly diagnosis of vascular thromboembolism include combination of signs and symptoms together with laboratory investigations that include routine lab investigations, d-dimer , protein s , protein c and antithrombin lll also imaging studies as doppler us , msct with angiography and mrv vascular thrombosis mainly treated with anticoagulant therapy with subcutaneous injection of low molecular weight heparin these medications prevent the clot from growing and decrease the risk of its breaking apart and causing further complications other treatments may include wearing compression stockings and applying warm packs to improve blood flow and pain caused by the clot

Eligibility criteria:
inclusion criteria : * age : from 1day to 18 years. * sex : both genders. * confirmed diagnosed cases, either symptomatic or asymptomatic venous and arterial thromboembolism established by an imaging study. * all patients admitted to the different units of children hospital including surgical unit. exclusion criteria : * age more than 18 years. * patient known to have sickle cell disease.
translation and reliability of faam-u

Conditions: Foot Injuries; Ankle Injuries

Summary: this study is designed to translate and validate the faam questionnaire to the urdu language, to interpret its psychometric properties, and to determine the reliability of scores obtained from the population of pakistan. the translated version of the gold standard tool will be used by the local population as well as urdu-speaking immigrants across the globe to better understand and report the severity of their symptoms. hence, to improve quality of life across cultures, there is a need of standard outcome measures in urdu language.


Eligibility criteria:
inclusion criteria: * ankle and foot disorders, referred by a general physician or surgeon, * conscious * ambulatory * able to write and read urdu language exclusion criteria: * inflammatory disease * vascular diseases * neural diseases * cancer
cisplatin combined with s-1 or paclitaxel as first-line treatment for metastatic esophageal squamous cell carcinoma

Conditions: Esophageal Squamous Cell Carcinoma

Summary: cisplatin combined with s-1 or paclitaxel as first-line treatment for metastatic esophageal squamous cell carcinoma


Eligibility criteria:
inclusion criteria: * histologically proven primary thoracic esophageal squamous cell carcinoma * not suitable for surgery or radio or chemical therapy * presence of at least one index lesion measurable by ct scan or mri radiation therapy ended at least 4 weeks, but part of the radiation does not as a measurable lesions * 18\~70 years * ps:0-1 * life expectancy of ≥ 3 months * wbc≥3.5×109/l,anc≥1.5×109/l, plt≥100×109/l, hb≥100g/l * tb ≤ 1.5unl, alt/ast ≤ 2.5×unl * scr≥60 ml/min * normal electrocardiogram (ecg) * can normal oral drugs * signed written informed consent exclusion criteria: * breast-feeding or pregnant women, no effective contraception if risk of conception exists * chronic diarrhea, enteritis, intestine obstruction which are not under control * esophageal obstruction cannot eat liquid completely, esophagus have deep ulcer perforation or hematemesis; esophageal cancer common complications such as anastomotic leakage, serious lung complications, etc. * a second primary tumor (except skin basal cell carcinoma) * the original serious heart disease, including: higher risk of congestive heart failure, unable to control arrhythmia, unstable angina, myocardial infarction, severe valvular heart disease, and resistant hypertension * with uncontrol nerve, mental illness or mental disorders, compliance is poor, can't cooperate with accounts and response to treatment; primary brain tumors or - cns metastases illness did not get a control, has obvious cranial hypertension or nerve mental symptoms * with bleeding tendency * has inherited bleeding evidence of physical or blood coagulation disorder * with clear chemotherapy drug allergy * other researchers believe that patients should not participate in this testing
cryotherapy against oral mucositis after high-dose melphalan

Conditions: Myeloma; Mucositis; Cryotherapy Effect

Summary: in this prospective, randomised, controlled, open-label, phase iii, non-inferiority clinical trial trial patients with a diagnosis of myeloma who were undergoing autologous hsct were randomised 1:1 to receive cryotherapy for 7 hours or 2 hours . oral mucositis was evaluated prospectively.

we searched medline and pubmed with the following phrases: "oral mucositis", "oral toxicity", "cryotherapy", "myeloma", "autologous haematopoietic stem cell transplantation", "randomised trial" and "high-dose melphalan". oral mucositis, which is a side effect of high-dose chemotherapy, has a major negative impact on the quality of life and survival of patients who undergoing autologous haematopoietic stem cell transplantation (auto-hsct). for patients with myeloma cryotherapy gives a significant reduction in oral mucositis. the mechanism of action is suggested to be vasoconstriction that is induced by the cooling of the oral mucosa, thereby protecting it from the cytotoxic effects of the chemotherapy. the therapeutic efficacy of cryotherapy in this setting has been confirmed in several trials, it is currently regarded as the standard of care prophylactic regimen for oral mucositis in patients undergoing auto-hsct for myeloma. however, the long duration of the treatment (7 hours), as reported in the original, placebo-controlled study in 2006, has been associated with significant discomfort for the patients, with negative consequences for compliance. uncontrolled trials have previously tested cryotherapy for less than 7 hours in patients with myeloma who receive auto-hsct. at the time of the planning of the current study in 2014, those results were not yet confirmed in any randomised trial. however last year a randomised trial was published, showing that 2-hour cryotherapy is equally as effective as 6-hour cryotherapy in preventing oral mucositis in patients with myeloma who are treated with high-dose melphalan. the present prospective, randomised study aimed to investigate whether 2 hours of cryotherapy is as effective as 7 hours of cryotherapy in protecting against oral mucositis those patients who are subjected to high-dose melphalan as a conditioning agent for auto-sct for myeloma.

Eligibility criteria:
inclusion criteria: myeloma, autologous hsct - exclusion criteria: -
immunogenicity and safety of s.flexneriza-s.sonnei bivalent conjugate vaccine in volunteers aged from 3 months to 5 years old

Conditions: Dysentery; Dysentery, Bacillary

Summary: the purpose of this study is to evaluate immunogenicity and safety of s.flexneriza-s.sonnei bivalent conjugate vaccine in healthy volunteers aged from 3 months to 5 years old.


Eligibility criteria:
inclusion criteria: * health infants and children aged from 3 months to 5 years old. * subject or legal representative who consent and has signed written informed consent. * subject and parent/guardian who is able to comply with all study procedures. * subject who did't receive blood products within 30 days ,immune with any live vaccine within 14 days and inactivated vaccine within 7 days before vaccination. * subject who haven't immuned with diarrhea vaccination,3-11 months health infants who haven't immuned with haemophilus b conjugate vaccination,or had a history of hib vaccination before the age of 1 but no history of vaccination after 1 year of age,and the interval between the day of the enrollment and the previous dose is more than one month. * axillary temperature ≤37.0 ℃. exclusion criteria: * febrile illness (temperature ≥ 38°c) in the 3 days or in the acute phase of the disease / active period. * subject who have symptoms such as diarrhea, abdominal pain, and pus and bloody stools in the past 3 days. * subject who are allergic to tetanus toxoid. * allergic history after vaccination. * immunodeficiency diseases patients (such as perianal abscess suggests that there may be immunodeficiency in infants and young children) who administered with immunosuppressive agents (≥14 days). * subject who are suffering from serious chronic diseases, cardiovascular disease,liver or kidney disease. * subject with congenital malformations, drug allergies, convulsions, epilepsy, history of craniocerebral trauma, encephalopathy and psychosis, or family history. * subject who diagnosis of thrombocytopenia or other history of coagulopathy may cause intramuscular contraindication. * children with abnormal labor（pregnancy week\ 42w）,birth weight (\ 4000g), asphyxia rescue history(only applicable to 3-5 months old group). * subject who plan to participate in or is in any other drug clinical trial. * any condition that, in the judgment of investigator, may affect trial assessment.
open-label trial on the effect of i.v. zoledronic acid 4 mg on bone density in hormone sensitive prostate cancer patients with bone metastasis

Conditions: Prostate Cancer

Summary: the purpose of this trial with zometa is to investigate the effect zometa 4 mg (zoledronic acid for injection in 100mg solution ) has in preventing associated bone loss in prostate cancer patients with bone metastasis when administered in conjunction with hormonal cancer therapy. this trial will seek to determine the effect of zometa in stabilizing and increasing bone mineral density in these patients. this prospective, open-label, single arm, multicenter study will enroll approximately 200 prostate cancer patients with a history of at least one documented bone lesion documented by bone scan or radiograph. patients must already be receiving hormone therapy and meet the following additional criteria: * 18 years of age or older * histologically confirmed diagnoses of prostate cancer * confirmed objective evidence of metastatic bone disease as evidenced by bone scan or radiograph * received or will receive hormonal treatment also know as androgen deprivation therapy with an lhrh agonist or other hormonal treatments throughout the course of this 12-month trial, patients will be identified based on the duration of established hormonal treatment at the time of enrollment. each patients duration of participation will be up to 56 weeks including a 4 week screening, 48 week treatment and a 4 week follow up.


Eligibility criteria:
inclusion criteria: * signed informed consent * age \> 18 years * histologically confirmed diagnosis of carcinoma of the prostate * objective evidence of metastatic disease to the bone as evidenced by bone scan or radiograph at any point since their diagnosis of prostate cancer * currently receiving, or will begin receiving, hormonal therapy with an lhrh agonist or other hormonal treatments for either \ 6 months * ecog performance status of 0, 1, or 2 exclusion criteria: * patients who are hormone sensitive without metastatic disease to the bone * patients who are hormone refractory typically defined as two or three consecutive increases in psa measured at least one month apart while on hormone therapy * patients who are not treated with lhrh agonist or other hormonal treatments * patients who are currently receiving diethylstilbestrol (des) or pc-spes * patients with another nonmalignant disease which would confound the evaluation of primary endpoints or prevent the patient complying with the protocol. * patients with abnormal renal function as evidenced by either a serum creatinine greater than 2 mg/dl or by a calculated creatinine clearance of 60 ml/minute or less * corrected (adjusted for serum albumin) serum calcium concentration \< 8.0 mg/dl (2.00 mmol/l)

Keywords: hormone-sensitive prostate cancer prostate cancer bone metastasis
machine learning to predict factors affecting rehabilitation length of stay and healthcare costs for neurological rehabilitation

Conditions: Stroke; Acquired Brain Injury; Traumatic Brain Injury; Brain Tumor; Central Nervous System Infections; Polytrauma

Summary: the aim of this retrospective study is to ascertain total direct costs, rehabilitation length of stay (rlos) and factors associated with rlos for neurological inpatient rehabilitation at the tertiary care hospital.

the aim of the study is to identify factors that influence rlos and the correlated costs for neurological rehabilitation in tertiary rehab using data extracted from epic. it is also aimed to identify the median direct costs to find out the main contributors to the costs in the local population. lastly, the study aims to utilise artificial intelligence or machine learning to analyse the compiled data to develop a predictive model. the model aspires to understand factors associated with extended rlos and to predict rlos of patients who require neurological rehabilitation, aiding preemptive measures.

Eligibility criteria:
inclusion criteria: • all patients who completed inpatient rehabilitation with the index conditions in their discharge summaries exclusion criteria: • did not complete inpatient rehabilitation as they are discharged against medical advice

Keywords: rehabilitation length of stay stroke traumatic brain injury brain tumour cancer trauma acquired brain injury healthcare hospitalisation costs
plasma pharmacological monitoring of m penicillins in methicillin-sensitive staphylococcus aureus bacteremia

Conditions: Staphylococcus Aureus Infection

Summary: the treatment of methicillin-sensitive staphylococcus aureus bacteremia is based on the first-line use of cefazolin or m penicillins (oxacillin and cloxacillin). the use of the latter is recommended at high doses (150-200 mg/kg/24h). in a study on infectious endocarditis, 52 of 56 patients with staphylococcal endocarditis treated with (cl)oxacillin were overdosed with the recommended doses. although the main mechanism of renal toxicity described for m penicillins is immunoallergic, a frequent overdose is observed in cases of acute renal failure with m penicillins. there is also a significant association between overdose and risk of neurological toxicity. the currently recommended treatment duration is a minimum of 14 days of iv treatment from the first negative blood culture, which leaves room for carrying out a plasma assay and possible dosage adjustment subsequently. overdose is a risk factor for nephrotoxicity and neurotoxicity. plasma level could be predictive of clinical success. systematic plasma dosing would reduce the risk of toxicity and improve the clinical cure rate.


Eligibility criteria:
inclusion criteria: * adult patient (≥18 years old) * having presented an infection with staphylococcus aureus and treated at the university hospitals of strasbourg between january 1, 2019 and december 31, 2022. exclusion criteria: - patient having expressed his opposition to the reuse of his data for scientific research purposes.

Keywords: staphylococcus aureus infection staphylococcus aureus bacteremia penicillins methicillin-sensitive cefazolin infectious endocarditis staphylococcal endocarditis oxacillin nephrotoxicity
epicardial adipose tissue thickness predicts obstructive coronary artery disease in acute coronary syndrome patients

Conditions: Acute Coronary Syndrome

Summary: epicardial adipose tissue (eat) is a visceral adipose tissue that surrounds the heart and the coronary arteries. it is metabolically active, secreting pro- and anti-inflammatory mediators and cytokines. with increasing eat volume, inflammatory activity increasing, which suggests that eat may locally influence atherosclerosis development in the coronary artery tree. the amount of eat is associated with cardiovascular disease risk factors as well as presence and progression of subclinical atherosclerosis. likewise, eat volume is increased in patient with prevalent and incident coronary artery disease manifestation. in the setting of acute coronary syndrome, eat was found to be associated with the timi risk score and syntax ii score. while ct imaging of the heart is the gold standard for eat quantification, transthoracic echocardiography allows for a quick and reliable assessment of eat thickness, as has been used in research studies and may qualify for routine eat assessment in clinical routine.however, currently data on how quantification of eat in clinical routine may impact patient management is lacking. we aim to investigate, whether quantification of eat thickness via transthoracic echocardiography enables improved risk stratification in patients presenting with acute chest pain to the emergency department.


Eligibility criteria:
inclusion criteria: * admission to the emergency department of the university hospital essen with acute chest pain suggestive of an acute coronary syndrome exclusion criteria: * known obstructive coronary artery disease prior to presentation, prior revascularization therapy, unwillingness to provide informed consent

Keywords: epicardial adipose tissue chest pain echocardiography coronary artery disease